We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mazor Robotics' CE Mark for Mazor X Platform to Drive Orders
Read MoreHide Full Article
Mazor Robotics Ltd. recently received CE Mark approval for its Mazor X Surgical Assurance platform. The approval will allow Mazor Robotics and its partner Medtronic (MDT - Free Report) to commercialize, co-promote and market the Mazor X platform, in countries that recognize CE Mark.
Mazor Robotics and Medtronic had signed a deal to distribute Mazor X (Mazor's robotic spine surgery system) in May 2016. Medtronic has made $40 million in third tranche investments in Mazor Robotics recently.
In this regard we note that, Mazor Robotics recently reported second-quarter 2017 revenues of approximately $15.5 million, compared with $8.3 million in the year-ago quarter. The revenue upside was driven by strong Mazor X system sales and increased procedure volumes. During the last reported second quarter, Mazor Robotics received purchase orders for 16 Mazor X systems in the United States. We expect the CE Mark to drive orders for the system.
According to a report by Mordor Intelligence, the global market for Spinal Surgery Devices has been estimated to reach a worth of $16.6 billion by 2021 at a CAGR of 5% during the 2016 to 2021 period. Considering the opportunities in this niche, we see the company’s latest development as a strategic one.
However, the company is facing tough competition within this industry from well-established players likeStryker Corporation (SYK - Free Report) and Zimmer Biomet Holdings, Inc. (ZBH - Free Report) .
Estimate Revision Trend
The estimate revision trend has been favorable for the company. For the current year, one estimate moved north compared with no movement in the opposite direction over the last two months. As a result, the Zacks Consensus Estimate for the full year has narrowed to a loss of 86 cents per share from a loss of 92 cents.
4 Stocks to Watch after the Massive Equifax Hack
Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?
Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor’s Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.
Image: Bigstock
Mazor Robotics' CE Mark for Mazor X Platform to Drive Orders
Mazor Robotics Ltd. recently received CE Mark approval for its Mazor X Surgical Assurance platform. The approval will allow Mazor Robotics and its partner Medtronic (MDT - Free Report) to commercialize, co-promote and market the Mazor X platform, in countries that recognize CE Mark.
Mazor Robotics and Medtronic had signed a deal to distribute Mazor X (Mazor's robotic spine surgery system) in May 2016. Medtronic has made $40 million in third tranche investments in Mazor Robotics recently.
In this regard we note that, Mazor Robotics recently reported second-quarter 2017 revenues of approximately $15.5 million, compared with $8.3 million in the year-ago quarter. The revenue upside was driven by strong Mazor X system sales and increased procedure volumes. During the last reported second quarter, Mazor Robotics received purchase orders for 16 Mazor X systems in the United States. We expect the CE Mark to drive orders for the system.
According to a report by Mordor Intelligence, the global market for Spinal Surgery Devices has been estimated to reach a worth of $16.6 billion by 2021 at a CAGR of 5% during the 2016 to 2021 period. Considering the opportunities in this niche, we see the company’s latest development as a strategic one.
However, the company is facing tough competition within this industry from well-established players likeStryker Corporation (SYK - Free Report) and Zimmer Biomet Holdings, Inc. (ZBH - Free Report) .
Estimate Revision Trend
The estimate revision trend has been favorable for the company. For the current year, one estimate moved north compared with no movement in the opposite direction over the last two months. As a result, the Zacks Consensus Estimate for the full year has narrowed to a loss of 86 cents per share from a loss of 92 cents.
4 Stocks to Watch after the Massive Equifax Hack
Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?
Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor’s Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.
Get the new Investing Guide now>>